Learn how viral shedding and infectivity testing support the safe clinical development of oncolytic virotherapies.

As oncolytic virus therapies continue to advance, robust viral shedding and infectivity testing are essential for evaluating product safety, biodistribution, and regulatory compliance. This webinar explores the analytical strategies used to develop and validate qPCR and infectivity assays that generate reliable data throughout clinical development.

Topics include:

• The role of viral shedding and infectivity testing in oncolytic virus clinical trials
• How qPCR assays support viral shedding and biodistribution assessments
• The importance of TCID₅₀ assays for measuring infectious virus viability
• Regulatory and technical considerations for developing and validating qPCR and infectivity assays
• Best practices for designing viral shedding and infectivity studies in clinical development

As oncolytic virotherapies continue to expand, comprehensive viral shedding and infectivity testing remains critical for demonstrating safety and supporting regulatory submissions. Discover practical approaches for developing robust molecular and infectivity assays that support successful clinical trials.